MacBeath Gavin 4
4 · TScan Therapeutics, Inc. · Filed Jun 15, 2023
Insider Transaction Report
Form 4
MacBeath Gavin
DirectorChief Executive Officer
Transactions
- Award
Stock Option (Right to Buy)
2023-06-13+1,121,300→ 1,121,300 totalExercise: $2.49Exp: 2033-06-12→ Voting Common Stock (1,121,300 underlying)
Footnotes (1)
- [F1]536,300 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on the one-year anniversary of May 24, 2023, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer. The remaining 585,000 shares subject to this option shall vest and become exercisable with respect to 25% of the shares on February 2, 2025, with the balance vesting thereafter in equal monthly installments over the next 36 months of continuous service to the Issuer, in each case subject to the Reporting Person's continued service at such time. This option was granted on May 24, 2023 subject to the approval of the Issuers' stockholders of an amendment to the TScan Therapeutics, Inc. 2021 Equity Incentive Plan, which was obtained on June 13, 2023.